Advanced Accelerator Applications USA, Inc drugs

4 results

  • locametz

    (kit for the preparation of gallium Ga 68 gozetotide)
    Advanced Accelerator Applications USA, Inc
    LOCAMETZ, after radiolabeling with gallium-68, is used for PET imaging of PSMA-positive lesions in men with prostate cancer, aiding in the detection of metastasis, recurrence based on elevated PSA levels, and selection of patients for PSMA-directed therapy.
    Medication Details

  • lutathera

    (Lutetium Lu 177 dotatate)
    Advanced Accelerator Applications USA, Inc
    LUTATHERA is indicated for treating adult and pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), encompassing foregut, midgut, and hindgut neuroendocrine tumors.
    Medication Details
    Drug Interactions

  • netspot

    (68Ga-DOTATATE)
    Advanced Accelerator Applications USA, Inc
    NETSPOT, after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) to localize somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
    Medication Details

  • pluvicto

    (lutetium Lu 177 vipivotide tetraxetan)
    Advanced Accelerator Applications USA, Inc
    PLUVICTO is indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibition and taxane-based chemotherapy.
    Medication Details